PURPOSE: To examine the outcomes with the AdVance XP and AdVance slings in the management of post-prostatectomy incontinence (PPI). METHODS: Eighty patients were treated with the AdVance resp. AdVance XP at one tertiary reference centre. The initial patients were implanted with the AdVance male sling with no associated surgery. Following the introduction of the AdVance XP sling, subsequent patients were implanted with the AdVance XP slings. Measurements included: daily pad usage, 24-h pad weight test, International Quality of Life Questionnaire, International Consultation on Incontinence Questionnaire Short Form and the Patient Global Impression of Improvement. Adverse events were recorded. RESULTS: Follow-up was available for 39 and 41 patients treated with the AdVance and AdVance XP slings, respectively. At a median follow-up of 24.7 months, 69.3 % of patients could be classified as cured or improved in the AdVance group and at a median follow-up of 11.9 months, 90.3 % of AdVance XP-treated patients. At 3-month follow-up, 96.8 and 97.3 % of patients could be classed as cured or improved in the AdVance and AdVance XP groups, respectively (not significant). There were no perioperative complications. Two AdVance and three AdVance XP serious post-operative complications were reported, which were resolved following treatment. QOL was improved in both treatment groups. CONCLUSIONS: Both the AdVance and the AdVance XP slings are effective and safe for the treatment of PPI.
PURPOSE: To examine the outcomes with the AdVance XP and AdVance slings in the management of post-prostatectomy incontinence (PPI). METHODS: Eighty patients were treated with the AdVance resp. AdVance XP at one tertiary reference centre. The initial patients were implanted with the AdVance male sling with no associated surgery. Following the introduction of the AdVance XP sling, subsequent patients were implanted with the AdVance XP slings. Measurements included: daily pad usage, 24-h pad weight test, International Quality of Life Questionnaire, International Consultation on Incontinence Questionnaire Short Form and the Patient Global Impression of Improvement. Adverse events were recorded. RESULTS: Follow-up was available for 39 and 41 patients treated with the AdVance and AdVance XP slings, respectively. At a median follow-up of 24.7 months, 69.3 % of patients could be classified as cured or improved in the AdVance group and at a median follow-up of 11.9 months, 90.3 % of AdVance XP-treated patients. At 3-month follow-up, 96.8 and 97.3 % of patients could be classed as cured or improved in the AdVance and AdVance XP groups, respectively (not significant). There were no perioperative complications. Two AdVance and three AdVance XP serious post-operative complications were reported, which were resolved following treatment. QOL was improved in both treatment groups. CONCLUSIONS: Both the AdVance and the AdVance XP slings are effective and safe for the treatment of PPI.
Authors: Donald M Bushnell; Mona L Martin; Kent H Summers; Jan Svihra; Christos Lionis; Donald L Patrick Journal: Qual Life Res Date: 2005-10 Impact factor: 4.147
Authors: Ricarda M Bauer; Margit E Mayer; Christian Gratzke; Irina Soljanik; Alexander Buchner; Patrick J Bastian; Christian G Stief; Christian Gozzi Journal: Eur Urol Date: 2009-07-29 Impact factor: 20.096
Authors: Ricarda M Bauer; Irina Soljanik; Claudius Füllhase; Alexander Karl; Armin Becker; Christian G Stief; Christian Gozzi Journal: BJU Int Date: 2010-09-30 Impact factor: 5.588
Authors: Peter Rehder; Michael J Mitterberger; Renate Pichler; Andrea Kerschbaumer; Bernhard Glodny Journal: BJU Int Date: 2010-12 Impact factor: 5.588
Authors: Ricarda M Bauer; Christian Gozzi; Benedikt Klehr; Alexander Kretschmer; Markus Grabbert; Peter Rehder; Florian May; Christian G Stief; Peter Gebhartl; Roland Homberg Journal: World J Urol Date: 2015-11-18 Impact factor: 4.226
Authors: Alexander Kretschmer; Alexander Buchner; Benedikt Leitl; Markus Grabbert; Anne Sommer; Wael Khoder; Christian Gozzi; Christian G Stief; Ricarda M Bauer Journal: Int Neurourol J Date: 2016-12-26 Impact factor: 2.835
Authors: Peter Rehder; Nina M Staudacher; Joerg Schachtner; Maria E Berger; Florian Schillfahrt; Verena Hauser; Raphael Mueller; Viktor Skradski; Wolfgang Horninger; Bernhard Glodny Journal: Adv Urol Date: 2016-01-31